OTCMKTS:SPHRY Starpharma (SPHRY) Stock Price, News & Analysis $0.75 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartShort Interest About Starpharma Stock (OTCMKTS:SPHRY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Starpharma alerts:Sign Up Key Stats Today's Range$0.75▼$0.7550-Day Range$0.54▼$0.7652-Week Range$0.52▼$1.33Volume3,200 shsAverage Volume4,798 shsMarket Capitalization$31.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewStarpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.Read More… Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Receive SPHRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter. Email Address SPHRY Stock News HeadlinesStarpharma Highlights Dendrimer Technology at Healthcare ConferenceNovember 18 at 2:01 AM | markets.businessinsider.comStarpharma Showcases Dendrimer Innovations at Microcap ConferenceOctober 29, 2024 | markets.businessinsider.comTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. November 21, 2024 | Wide Moat Research (Ad)Starpharma Holdings Ltd. ADRMarch 14, 2024 | wsj.comStarpharma's VivaGel Approval Denied By FDAFebruary 19, 2024 | markets.businessinsider.comASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pcFebruary 18, 2024 | msn.comStarpharma Holdings Ltd SPLJanuary 19, 2024 | morningstar.comStarpharma Holdings LimitedJanuary 6, 2024 | afr.comSee More Headlines SPHRY Stock Analysis - Frequently Asked Questions How have SPHRY shares performed this year? Starpharma's stock was trading at $1.2440 at the start of the year. Since then, SPHRY shares have decreased by 39.7% and is now trading at $0.75. View the best growth stocks for 2024 here. How do I buy shares of Starpharma? Shares of SPHRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today11/21/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolOTCMKTS:SPHRY CUSIPN/A CIKN/A Webwww.starpharma.com Phone(138) 532-2700Fax61-3-9510-5955Employees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.07 Current Ratio4.94 Quick Ratio4.58 Sales & Book Value Annual Sales$6.40 million Price / Sales4.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.45 per share Price / Book1.67Miscellaneous Outstanding Shares41,810,000Free FloatN/AMarket Cap$31.36 million OptionableNot Optionable Beta1.06 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (OTCMKTS:SPHRY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Starpharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Starpharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.